Literature DB >> 20593238

Detection of drug related problems in an interdisciplinary health care model for rural areas in Germany.

Thomas Fiss1, Christoph Alexander Ritter, Dietrich Alte, Neeltje van den Berg, Wolfgang Hoffmann.   

Abstract

OBJECTIVE: The disparity between an increasing complexity of patients' treatment and the declining number of general practitioners (GP) require action. The AGnES-concept (general practitioner-relieving, community-based, e-health assisted, systemic intervention) is based on the delegation of original physician-activities to qualified AGnES-practice assistants. Purposes of AGnES part 1 were to determine the feasibility of community-based home medication reviews (HMR) and the establishment of a health professional network to identify drug related problems (DRP) in the domicile of elderly patients. Two consecutive studies (AGNES 2 + 3) were conducted to implement HMR.
SETTING: General practices on the isle of Rugia in Mecklenburg-Western Pomerania, a German rural area. Patients who receive regular home visits by their GP were addressed.
METHOD: Study-instruments for the feasibility study (AGnES 1) were designed by an expert panel and modified for the implementation (AGnES 2 + 3) studies. HMR were conducted by additionally qualified AGnES-practice assistants regarding DRP like drug-drug interaction (DDI), adverse drug reactions (ADR), and compliance. DRP-selection was inspired by the coding system Pi-Doc. Pharmacists checked DRP and intervened, if necessary. 18 (AGnES 1) and 60 (AGnES 2 + 3) geriatric patients received a minimum of two home visits by an AGnES-practice assistant. MAIN OUTCOME MEASURE: Feasibility was assessed by patients' satisfaction with care provided by the AGnES-practice assistant. For implementation reported DRP and the conducted interventions were evaluated.
RESULTS: During AGnES 1 a documentation sheet was developed and tested. 56 potential DDI were identified. 37 of 112 drugs which caused potential interactions were attributed to OTC medication and food components. 84% of respondents judged the systematic evaluation of their pharmacotherapy as helpful. During AGnES 2 + 3 local pharmacists identified DDIs in 45% of patients. Seven patients (11.6%) reported at least one ADR attributable to their current medication. Those patients who received a second HMR (n = 29) during AGnES 2 + 3 rated the HMR as reasonable 65.5% (n = 19), and partly reasonable 24.1% (n = 7).
CONCLUSIONS: By comprehensive HMR conducted by AGnES-practice assistants in delegation of the patients' GPs in cooperation with local pharmacists we could identify a considerable prevalence of DRP under real-life conditions. Further studies should recruit more participants including a control group with usual care.

Entities:  

Mesh:

Year:  2010        PMID: 20593238     DOI: 10.1007/s11096-010-9409-6

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  23 in total

Review 1.  Health-related quality of life measurement in pharmaceutical care. Targeting an outcome that matters.

Authors:  Nadir M Kheir; J W Foppe van Mil; John P Shaw; Janie L Sheridan
Journal:  Pharm World Sci       Date:  2004-06

2.  Home medication review. A personal experience in rural Tasmania.

Authors:  A K M Fakhruzzaman Bhuiyan
Journal:  Aust Fam Physician       Date:  2004-08

Review 3.  Drug-related problem classification systems.

Authors:  J W Foppe van Mil; L O Tommy Westerlund; Kurt E Hersberger; Marion A Schaefer
Journal:  Ann Pharmacother       Date:  2004-03-30       Impact factor: 3.154

4.  Adverse drug reaction monitoring--cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions.

Authors:  N Muehlberger; S Schneeweiss; J Hasford
Journal:  Pharmacoepidemiol Drug Saf       Date:  1997-10       Impact factor: 2.890

5.  Trends in risk factor control in Germany 1984-1998: high blood pressure and total cholesterol.

Authors:  Ulrich Laaser; Juergen Breckenkamp
Journal:  Eur J Public Health       Date:  2005-08-10       Impact factor: 3.367

6.  Adverse drug event reporting in intensive care units: a survey of current practices.

Authors:  Sandra L Kane-Gill; John W Devlin
Journal:  Ann Pharmacother       Date:  2006-07-18       Impact factor: 3.154

7.  Clinical medication review by a pharmacist of elderly people living in care homes--randomised controlled trial.

Authors:  Arnold Geoffrey Zermansky; David Phillip Alldred; Duncan Robert Petty; David K Raynor; Nick Freemantle; Joanne Eastaugh; Peter Bowie
Journal:  Age Ageing       Date:  2006-08-12       Impact factor: 10.668

8.  Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners.

Authors:  Elizabeth Roughead; Nicole Pratt; Robert Peck; Andrew Gilbert
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-07       Impact factor: 2.890

Review 9.  Epidemiology of drug-drug interactions as a cause of hospital admissions.

Authors:  C A Jankel; L K Fitterman
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

10.  Implementing telemonitoring in the daily routine of a GP practice in a rural setting in northern Germany.

Authors:  Claudia Terschüren; Konstanze Fendrich; Neeltje van den Berg; Wolfgang Hoffmann
Journal:  J Telemed Telecare       Date:  2007       Impact factor: 6.184

View more
  9 in total

1.  Cooperation between community pharmacists and general practitioners in eastern Germany: attitudes and needs.

Authors:  Anna-Franziska Wüstmann; Carsten Haase-Strey; Thomas Kubiak; Christoph Alexander Ritter
Journal:  Int J Clin Pharm       Date:  2013-04-11

Review 2.  Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review.

Authors:  Marlies M E Geurts; Jaap Talsma; Jacobus R B J Brouwers; Johan J de Gier
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

3.  Effects of a three party healthcare network on the incidence levels of drug related problems.

Authors:  Thomas Fiß; Claudia Meinke-Franze; Neeltje van den Berg; Wolfgang Hoffmann
Journal:  Int J Clin Pharm       Date:  2013-07-14

Review 4.  Prevalence of drug interactions in elderly patients with multimorbidity in primary care.

Authors:  Susana Sánchez-Fidalgo; Maria Isabel Guzmán-Ramos; Mercedes Galván-Banqueri; Máximo Bernabeu-Wittel; Bernardo Santos-Ramos
Journal:  Int J Clin Pharm       Date:  2017-02-25

5.  Healthcare Provider Perspectives on Digital and Interprofessional Medication Management in Chronically Ill Older Adults of Turkish Descent in Germany: A Qualitative Structuring Content Analysis.

Authors:  Rona Bird; Ilknur Özer-Erdogdu; Meryem Aslan; Hürrem Tezcan-Güntekin
Journal:  Front Public Health       Date:  2022-06-02

6.  Medication management for people with dementia in primary care: description of implementation in the DelpHi study.

Authors:  Thomas Fiß; Jochen René Thyrian; Diana Wucherer; Grit Aßmann; Ingo Kilimann; Stefan J Teipel; Wolfgang Hoffmann
Journal:  BMC Geriatr       Date:  2013-11-13       Impact factor: 3.921

7.  Unprescribed and unnoticed: Retrospective chart review of adverse events of interactions between antidepressants and over-the-counter drugs.

Authors:  Jarosław Woroń; Adrian Andrzej Chrobak; Daniel Ślęzak; Marcin Siwek
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

8.  Prevalence and determinants of controlled hypertension in a German population cohort.

Authors:  Neeltje van den Berg; Claudia Meinke-Franze; Thomas Fiss; Sebastian E Baumeister; Wolfgang Hoffmann
Journal:  BMC Public Health       Date:  2013-06-19       Impact factor: 3.295

9.  Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial.

Authors:  Jochen René Thyrian; Thomas Fiß; Adina Dreier; Georgia Böwing; Aniela Angelow; Sven Lueke; Stefan Teipel; Steffen Fleßa; Hans Jörgen Grabe; Harald Jürgen Freyberger; Wolfgang Hoffmann
Journal:  Trials       Date:  2012-05-10       Impact factor: 2.279

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.